Medicine and Dentistry
Acute Kidney Injury
12%
Adriamycin Bleomycin Vinblastine Dacarbazine
12%
Anaplastic Lymphoma Kinase
12%
Androgen Deprivation Therapy
26%
Androgen Suppression
12%
Arm
24%
Breast Cancer
16%
Cancer Registry
24%
Cancer Treatment
86%
Chemotherapy
14%
Childhood Cancer
24%
Clinical Research
43%
Clinical Trial
35%
Clinical Trial Design
12%
Cohort Analysis
13%
Colorectal Liver Metastasis
12%
Diagnosis
21%
Diagnostic Test
14%
Disease
37%
Distant Metastasis
12%
External Beam Radiotherapy
13%
Hazard Ratio
24%
Hodgkin's Lymphoma
26%
Leiomyosarcoma
13%
Male Breast Cancer
12%
Malignant Neoplasm
43%
Meta-Analysis
60%
Metastatic Kidney Cancer
12%
Neoplasm
20%
Nephrectomy
12%
Osteosarcoma
24%
Overall Survival
25%
Patient-Data
14%
Phase II Trials
15%
Plasma Cell Granuloma
12%
Polyethylene Terephthalate
12%
Pooled Analysis
24%
Post-Hoc Analysis
12%
Progression Free Survival
26%
Prostate Cancer
60%
Prostate Specific Antigen
15%
Radiation Dose Escalation
16%
Radiation Therapy
53%
Schistosoma Mansoni
12%
Soft Tissue Sarcoma
24%
Sunitinib
12%
Surgery
12%
Survival Rate
14%
Symptomatic Treatment
13%
Systematic Review
12%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Kidney Failure
12%
Adverse Event
9%
Anaplastic Lymphoma Kinase
12%
Androgen
26%
Anticonvulsive Agent
12%
Bioavailability
24%
Breast Cancer
8%
Cancer Registry
24%
Carcinoma
12%
Clinical Research
12%
Clinical Trial
30%
Clinical Trial Design
12%
Cohort Study
13%
Congenital Malformation
12%
Crizotinib
12%
Cryptococcal Meningitis
12%
Disease
22%
Distant Metastasis
12%
Distant Metastasis Free Survival
7%
Flucytosine
24%
Hepatitis B
12%
Hospital Mortality
12%
Kidney Cancer
12%
Leiomyosarcoma
13%
Liposarcoma
12%
Loiasis
12%
Malignant Neoplasm
100%
Malnutrition
12%
Metastasis Free Survival
12%
Microfilariasis
12%
Nivolumab
12%
Normal Human
12%
Osteosarcoma
24%
Overall Survival
27%
Pharmacokinetics
7%
Phase II Trials
15%
Plasma Cell Granuloma
12%
Prevalence
23%
Progression Free Survival
26%
Prostate Cancer
48%
Prostate Specific Antigen
18%
Psychotropic Agent
12%
Randomized Clinical Trial
12%
Soft Tissue Sarcoma
24%
Stillbirth
12%
Sunitinib
12%
Survival Rate
14%
Sustained Release
24%
Synovial Sarcoma
12%
Tablet
13%